Fisher & Paykel Healthcare Receives FDA Warning

Fisher & Paykel Healthcare Receives FDA Warning

Auckland, New Zealand, 9 February 2007 - Fisher & Paykel Healthcare
Corporation Limited (NZSX:FPH, ASX:FPH) advises that its US operating
company, Fisher & Paykel Healthcare Inc., has received a warning letter from
the United States Food and Drug Administration (FDA).

The FDA's warning letter relates to deviations from the US Quality System
regulation observed during an inspection of the company's California sales
and distribution facility in late 2006.

Since the FDA inspection, Fisher & Paykel Healthcare has implemented a
number of immediate corrective actions and has been in close communication
with the FDA to address the inspectional observations. The company
continues to work collaboratively with the FDA to ensure that any remaining
issues are promptly resolved to the FDA's satisfaction.

The company believes it will fully satisfy the FDA's requirements and that
there will be no material affect on its business.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer
of heated humidification products and systems for use in respiratory care
and the treatment of obstructive sleep apnea. It also offers an innovative
range of neonatal care products. The company's products are sold in over
110 countries worldwide. For more information about the company visit
www.fphcare.com

Ends

© Scoop Media